Market Overview:
The global kidney cancer therapy market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth is attributed to the increasing incidence of kidney cancer, technological advancements in the field of treatment, and rising awareness about available treatments options. Based on type, the global kidney cancer therapy market is segmented into monoclonal antibody, mTOR inhibitors, kinase inhibitors, and other therapies. Monoclonal antibody-based therapies are expected to dominate the market during the forecast period owing to their high efficacy and safety profile. Based on application, renal cell carcinoma (RCC) accounted for majority of the share in 2017 and is projected to maintain its dominance during the forecast period.
Product Definition:
Kidney cancer therapy is the use of treatments to destroy or control kidney cancer. The main types of kidney cancer therapies are surgery, radiation therapy, and chemotherapy.
Monoclonal Antibody:
Monoclonal antibody is a type of biological therapy that targets and binds to cancer cells. Monoclonal antibodies are used in various types of cancers such as renal cell carcinoma, melanoma, breast carcinoma, prostate carcinomatosis and others. The most common use of monoclonal antibody is in the treatment of cancerous cells including those that have spread to other parts of the body (metastatic).
mTOR Inhibitors:
TOR (target of Rapamycin) inhibitors are a new class of drugs that prevent mTOR-mediated phosphorylation and activation of AKT, which is associated with the inhibition of tumor angiogenesis and metastasis. TOR inhibitors have shown promising results in preclinical models for renal cancer. These drugs have been found to inhibit the growth rate and invasiveness in vitro as well as in vivo models for renal cell carcinoma.
Application Insights:
RCC accounted for the largest share of revenue in 2017 owing to its high prevalence. RCC is also one of the most treatable forms of kidney cancer, with a five-year survival rate of over 90%. The introduction and approval of several new drugs in recent years has led to an increase in their usage for RCC treatment. It was approved by FDA for treatment purposes under rare category because it shows resistance towards chemotherapy and radiation therapy; however it does not affect patients' ability to receive hormonal therapy or surgery.
Treatment methods such as immunotherapy, chemotherapy and/or radiotherapy are used depending upon the stage & type of cancer patient's illness as well as their age group & general health condition.
Regional Analysis:
North America dominated the global kidney cancer therapy market in 2017. This can be attributed to the presence of key players, high adoption of novel therapies, and favorable government initiatives. For instance, in 2014 Novartis AG announced that it was making a USD X million donation to The Kidney Foundation for research on chronic kidney diseases.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising disposable income coupled with increasing healthcare spending by governments as well as private entities. Moreover, growing awareness about early diagnosis will also boost revenue generation in Asia Pacific region over the forecast period. Increasing incidence of RCC and TCC has led major pharmaceutical companies such as Pfizer Inc., Merck & Co., Inc.; Johnson & Johnson; Bristol-Myers Squibb Company; AbbVie Inc.
Growth Factors:
- Increasing incidence of kidney cancer
- Growing awareness about kidney cancer and its treatment options
- Rising demand for better and more effective therapies for kidney cancer patients
- Technological advancements in the field of kidney cancer therapy
- Availability of government funding for research on new treatments for kidney cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Kidney Cancer Therapy Market Research Report
By Type
Monoclonal Antibody, mTOR Inhibitors, Kinase Inhibitors, Other
By Application
Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC)
By Companies
Pfizer, Bristol-Myers Squibb, Roche, GSK, Novartis, Bayer, Merck & Co., Exelixis, Takeda, Eisai, CTTQ, AVEO Oncology, Everest Pharm, Cipla, NATCO, Beacon Pharma, SAMARTH
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
206
Number of Tables & Figures
145
Customization Available
Yes, the report can be customized as per your need.
Global Kidney Cancer Therapy Market Report Segments:
The global Kidney Cancer Therapy market is segmented on the basis of:
Types
Monoclonal Antibody, mTOR Inhibitors, Kinase Inhibitors, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Bristol-Myers Squibb
- Roche
- GSK
- Novartis
- Bayer
- Merck & Co.
- Exelixis
- Takeda
- Eisai
- CTTQ
- AVEO Oncology
- Everest Pharm
- Cipla
- NATCO
- Beacon Pharma
- SAMARTH
Highlights of The Kidney Cancer Therapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibody
- mTOR Inhibitors
- Kinase Inhibitors
- Other
- By Application:
- Renal Cell Carcinoma (RCC)
- Transitional Cell Carcinoma (TCC)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Kidney Cancer Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Kidney cancer therapy is the treatment of kidney cancer with medications and/or surgery.
Some of the major companies in the kidney cancer therapy market are Pfizer, Bristol-Myers Squibb, Roche, GSK, Novartis, Bayer, Merck & Co., Exelixis, Takeda, Eisai, CTTQ, AVEO Oncology, Everest Pharm, Cipla, NATCO, Beacon Pharma, SAMARTH.
The kidney cancer therapy market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Kidney Cancer Therapy Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Kidney Cancer Therapy Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Kidney Cancer Therapy Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Kidney Cancer Therapy Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Kidney Cancer Therapy Market Size & Forecast, 2018-2028 4.5.1 Kidney Cancer Therapy Market Size and Y-o-Y Growth 4.5.2 Kidney Cancer Therapy Market Absolute $ Opportunity
Chapter 5 Global Kidney Cancer Therapy Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Kidney Cancer Therapy Market Size Forecast by Type
5.2.1 Monoclonal Antibody
5.2.2 mTOR Inhibitors
5.2.3 Kinase Inhibitors
5.2.4 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Kidney Cancer Therapy Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Kidney Cancer Therapy Market Size Forecast by Applications
6.2.1 Renal Cell Carcinoma (RCC)
6.2.2 Transitional Cell Carcinoma (TCC)
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Kidney Cancer Therapy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Kidney Cancer Therapy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Kidney Cancer Therapy Analysis and Forecast
9.1 Introduction
9.2 North America Kidney Cancer Therapy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Kidney Cancer Therapy Market Size Forecast by Type
9.6.1 Monoclonal Antibody
9.6.2 mTOR Inhibitors
9.6.3 Kinase Inhibitors
9.6.4 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Kidney Cancer Therapy Market Size Forecast by Applications
9.10.1 Renal Cell Carcinoma (RCC)
9.10.2 Transitional Cell Carcinoma (TCC)
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Kidney Cancer Therapy Analysis and Forecast
10.1 Introduction
10.2 Europe Kidney Cancer Therapy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Kidney Cancer Therapy Market Size Forecast by Type
10.6.1 Monoclonal Antibody
10.6.2 mTOR Inhibitors
10.6.3 Kinase Inhibitors
10.6.4 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Kidney Cancer Therapy Market Size Forecast by Applications
10.10.1 Renal Cell Carcinoma (RCC)
10.10.2 Transitional Cell Carcinoma (TCC)
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Kidney Cancer Therapy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Kidney Cancer Therapy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Kidney Cancer Therapy Market Size Forecast by Type
11.6.1 Monoclonal Antibody
11.6.2 mTOR Inhibitors
11.6.3 Kinase Inhibitors
11.6.4 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Kidney Cancer Therapy Market Size Forecast by Applications
11.10.1 Renal Cell Carcinoma (RCC)
11.10.2 Transitional Cell Carcinoma (TCC)
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Kidney Cancer Therapy Analysis and Forecast
12.1 Introduction
12.2 Latin America Kidney Cancer Therapy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Kidney Cancer Therapy Market Size Forecast by Type
12.6.1 Monoclonal Antibody
12.6.2 mTOR Inhibitors
12.6.3 Kinase Inhibitors
12.6.4 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Kidney Cancer Therapy Market Size Forecast by Applications
12.10.1 Renal Cell Carcinoma (RCC)
12.10.2 Transitional Cell Carcinoma (TCC)
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Kidney Cancer Therapy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Kidney Cancer Therapy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Kidney Cancer Therapy Market Size Forecast by Type
13.6.1 Monoclonal Antibody
13.6.2 mTOR Inhibitors
13.6.3 Kinase Inhibitors
13.6.4 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Kidney Cancer Therapy Market Size Forecast by Applications
13.10.1 Renal Cell Carcinoma (RCC)
13.10.2 Transitional Cell Carcinoma (TCC)
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Kidney Cancer Therapy Market: Competitive Dashboard
14.2 Global Kidney Cancer Therapy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Bristol-Myers Squibb
14.3.3 Roche
14.3.4 GSK
14.3.5 Novartis
14.3.6 Bayer
14.3.7 Merck & Co.
14.3.8 Exelixis
14.3.9 Takeda
14.3.10 Eisai
14.3.11 CTTQ
14.3.12 AVEO Oncology
14.3.13 Everest Pharm
14.3.14 Cipla
14.3.15 NATCO
14.3.16 Beacon Pharma
14.3.17 SAMARTH